文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-DOTATATE诱导治疗使局部进展或寡转移胰腺神经内分泌肿瘤患者获得长期生存

Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-03-01

回顾性队列研究纳入49例接受177Lu-DOTATATE诱导治疗的胰腺神经内分泌肿瘤患者,其中26例后续接受根治性胰腺手术。PRRT+手术组部分客观缓解率为62%,仅PRRT组为26%(p=0.02);PRRT+手术组中位总生存14.7年(95%CI 5.9-23.6),仅PRRT组为5.5年(95%CI 4.5-6.5)(p=0.003)。作者认为早期PRRT后手术与良好长期结局相关,可考虑用于选择性血管侵犯和/或复发风险增高的患者。

要点

  • PRRT+手术组部分客观缓解率为62%,仅PRRT组为26%(p=0.02)。
  • PRRT+手术组中位总生存14.7年(95%CI 5.9-23.6),仅PRRT组为5.5年(95%CI 4.5-6.5)(p=0.003)。
  • 倾向评分校正后手术与总生存无显著关联。

核心结论

  • 早期给予PRRT后手术与局部进展或寡转移胰腺神经内分泌肿瘤患者的良好长期结局相关。
  • 作者认为可考虑用于选择性血管侵犯和/或复发风险增高的患者。

研究设计与样本

  • 回顾性队列研究,纳入接受177Lu-DOTATATE诱导治疗的胰腺神经内分泌肿瘤患者,共49例,其中26例后续接受根治性胰腺手术。

主要发现

  • PRRT+手术组部分客观缓解率为62%,仅PRRT组为26%(p=0.02)。
  • 在所有至少有一根血管受累的患者中,38%观察到肿瘤-血管界面的降期。
  • PRRT+手术组中位总生存为14.7年(95%CI 5.9-23.6),仅PRRT组为5.5年(95%CI 4.5-6.5)(p=0.003)。
  • PRRT+手术组中位无进展生存为5.3年(95%CI 2.4-8.1),仅PRRT组为3.0年(95%CI 1.6-4.4)(p=0.02)。
  • Cox比例风险分析中,经倾向评分校正累积活度、体能状态、PRRT后肿瘤大小和肿瘤分级后,手术与总生存无显著关联。

临床怎么用

  • 作者认为早期PRRT后手术可考虑用于选择性血管侵犯和/或复发风险增高的局部进展或寡转移胰腺神经内分泌肿瘤患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE induces objective response in up to 57% of pancreatic neuroendocrine neoplasms (panNENs). Therefore, PRRT may comprise a downstaging option for panNEN patients who are not eligible for upfront curative surgery or are at high risk for recurrence. The aim of this study was to assess the potency of induction PRRT for locally advanced panNENs and to evaluate the effect of surgery after PRRT on overall survival (OS). METHODS: Retrospective cohort study of panNEN patients treated with induction 177Lu-DOTATATE. RESULTS: After PRRT, 26 out of 49 patients underwent pancreatic surgery with curative intent (PRRT + surgery). Partial objective response was obtained in 62% of the PRRT + surgery group versus 26% of the patients not undergoing panNEN surgery (PRRT-only group, p = 0.02). Downstaging in tumour-vessel interface was observed in 38% of all patients with at least one involved vessel. Median OS was 14.7 years (95% CI 5.9-23.6) for the PRRT + surgery group compared to 5.5 years (95% CI 4.5-6.5) for the PRRT-only group (p = 0.003). In the Cox proportional hazards analysis, surgery was not significantly associated with OS after propensity score adjustment with cumulative activity, performance status, tumour size after PRRT, and tumour grade. Median progression-free survival was 5.3 years (95% CI 2.4-8.1) for the PRRT + surgery group and 3.0 years (95% CI 1.6-4.4) for the PRRT-only group (p = 0.02). CONCLUSION: Early administration of PRRT followed by surgery is associated with favourable long-term outcomes in patients with locally advanced or oligometastatic panNEN and can be considered for selected patients with vascular involvement and/or increased risk of recurrence.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Minczeles NS, van Eijck CHJ, van Gils MJ, et al. Induction therapy with 177Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. Eur J Nucl Med Mol Imaging. 2022. PMID: 35230492. doi:10.1007/s00259-022-05734-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。